Concepts (122)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 3 | 2022 | 3021 | 0.760 |
Why?
|
| Trastuzumab | 1 | 2019 | 73 | 0.640 |
Why?
|
| Receptor, ErbB-2 | 2 | 2019 | 247 | 0.600 |
Why?
|
| Paclitaxel | 1 | 2019 | 475 | 0.570 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2016 | 17 | 0.560 |
Why?
|
| Naphthalenes | 1 | 2016 | 42 | 0.550 |
Why?
|
| Cost-Benefit Analysis | 1 | 2019 | 465 | 0.540 |
Why?
|
| Imidazoles | 1 | 2016 | 140 | 0.520 |
Why?
|
| Receptors, Androgen | 1 | 2016 | 119 | 0.500 |
Why?
|
| Lymph Nodes | 1 | 2019 | 552 | 0.500 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2016 | 163 | 0.440 |
Why?
|
| Coronary Artery Bypass, Off-Pump | 2 | 2011 | 40 | 0.410 |
Why?
|
| Burkitt Lymphoma | 1 | 2012 | 32 | 0.410 |
Why?
|
| Boronic Acids | 1 | 2012 | 54 | 0.410 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2012 | 44 | 0.410 |
Why?
|
| Pyrazines | 1 | 2012 | 91 | 0.390 |
Why?
|
| Stomach Neoplasms | 3 | 2020 | 287 | 0.370 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2012 | 152 | 0.370 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2024 | 2503 | 0.360 |
Why?
|
| Meningioma | 1 | 2010 | 62 | 0.350 |
Why?
|
| Meningeal Neoplasms | 1 | 2010 | 66 | 0.350 |
Why?
|
| Internal Mammary-Coronary Artery Anastomosis | 1 | 2010 | 9 | 0.350 |
Why?
|
| Neuroendocrine Tumors | 1 | 2011 | 122 | 0.340 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2018 | 585 | 0.330 |
Why?
|
| Pancreatic Neoplasms | 2 | 2011 | 682 | 0.320 |
Why?
|
| Myocardial Ischemia | 1 | 2010 | 162 | 0.310 |
Why?
|
| Transcriptome | 1 | 2012 | 655 | 0.280 |
Why?
|
| Treatment Outcome | 7 | 2024 | 8218 | 0.240 |
Why?
|
| Aged, 80 and over | 6 | 2024 | 6771 | 0.240 |
Why?
|
| CTLA-4 Antigen | 1 | 2024 | 140 | 0.230 |
Why?
|
| Female | 14 | 2024 | 46401 | 0.230 |
Why?
|
| Liver Neoplasms | 1 | 2010 | 753 | 0.230 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2024 | 173 | 0.220 |
Why?
|
| Oligopeptides | 1 | 2024 | 188 | 0.210 |
Why?
|
| Aged | 11 | 2024 | 19158 | 0.210 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 2327 | 0.210 |
Why?
|
| Dexamethasone | 1 | 2024 | 343 | 0.200 |
Why?
|
| Policy | 1 | 2022 | 35 | 0.200 |
Why?
|
| Neoplasm Staging | 2 | 2019 | 2003 | 0.200 |
Why?
|
| Adenocarcinoma | 3 | 2020 | 1185 | 0.200 |
Why?
|
| Risk Reduction Behavior | 1 | 2022 | 97 | 0.190 |
Why?
|
| Tamoxifen | 1 | 2022 | 168 | 0.190 |
Why?
|
| Esophageal Neoplasms | 2 | 2020 | 333 | 0.180 |
Why?
|
| Adult | 8 | 2024 | 26704 | 0.180 |
Why?
|
| Humans | 17 | 2024 | 89613 | 0.180 |
Why?
|
| Mastectomy | 1 | 2022 | 246 | 0.170 |
Why?
|
| Multiple Myeloma | 1 | 2024 | 331 | 0.170 |
Why?
|
| Middle Aged | 9 | 2024 | 26012 | 0.160 |
Why?
|
| Glucuronosyltransferase | 1 | 2020 | 186 | 0.160 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 200 | 0.150 |
Why?
|
| Ovarian Neoplasms | 1 | 2024 | 768 | 0.150 |
Why?
|
| Stroke Volume | 2 | 2011 | 465 | 0.150 |
Why?
|
| Antibodies, Monoclonal | 1 | 2024 | 1394 | 0.150 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 477 | 0.150 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2016 | 20 | 0.130 |
Why?
|
| Postmenopause | 1 | 2016 | 102 | 0.130 |
Why?
|
| Hormones | 1 | 2016 | 139 | 0.130 |
Why?
|
| Breast Neoplasms, Male | 1 | 2016 | 31 | 0.130 |
Why?
|
| Receptors, Progesterone | 1 | 2016 | 175 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 951 | 0.120 |
Why?
|
| Receptors, Estrogen | 1 | 2016 | 394 | 0.120 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2013 | 33 | 0.110 |
Why?
|
| Neoadjuvant Therapy | 1 | 2016 | 375 | 0.100 |
Why?
|
| Carcinoma, Small Cell | 1 | 2013 | 133 | 0.100 |
Why?
|
| Genes, myc | 1 | 2012 | 40 | 0.100 |
Why?
|
| Bortezomib | 1 | 2012 | 80 | 0.100 |
Why?
|
| Young Adult | 2 | 2022 | 6368 | 0.100 |
Why?
|
| Immunoglobulin M | 1 | 2012 | 163 | 0.100 |
Why?
|
| Herpesvirus 4, Human | 1 | 2012 | 120 | 0.100 |
Why?
|
| Male | 10 | 2024 | 42488 | 0.100 |
Why?
|
| Fatal Outcome | 1 | 2012 | 296 | 0.100 |
Why?
|
| Translocation, Genetic | 1 | 2012 | 265 | 0.100 |
Why?
|
| Hyperamylasemia | 1 | 2011 | 2 | 0.090 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 2011 | 14 | 0.090 |
Why?
|
| Heart Arrest, Induced | 1 | 2011 | 29 | 0.090 |
Why?
|
| Osteoclasts | 1 | 2011 | 35 | 0.090 |
Why?
|
| Prospective Studies | 3 | 2024 | 4309 | 0.090 |
Why?
|
| Electrocardiography | 2 | 2011 | 497 | 0.090 |
Why?
|
| Pancreatitis | 1 | 2011 | 86 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 1281 | 0.090 |
Why?
|
| Neoplasms, Second Primary | 1 | 2012 | 260 | 0.090 |
Why?
|
| Prognosis | 1 | 2016 | 3785 | 0.080 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2011 | 331 | 0.070 |
Why?
|
| Survival Rate | 1 | 2010 | 1887 | 0.060 |
Why?
|
| Drug Administration Schedule | 2 | 2018 | 865 | 0.060 |
Why?
|
| Signal Transduction | 1 | 2016 | 3397 | 0.060 |
Why?
|
| Ipilimumab | 1 | 2024 | 60 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2018 | 1928 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2024 | 181 | 0.050 |
Why?
|
| Neoplasms | 1 | 2018 | 3054 | 0.050 |
Why?
|
| Follow-Up Studies | 1 | 2010 | 3659 | 0.050 |
Why?
|
| Time Factors | 1 | 2010 | 5337 | 0.050 |
Why?
|
| Prostatic Neoplasms | 1 | 2012 | 1734 | 0.050 |
Why?
|
| Leucovorin | 1 | 2020 | 223 | 0.040 |
Why?
|
| Dideoxynucleosides | 1 | 2018 | 2 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 279 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2020 | 550 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 337 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 97 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 2018 | 195 | 0.030 |
Why?
|
| United States | 1 | 2010 | 7050 | 0.030 |
Why?
|
| Animals | 1 | 2016 | 27481 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2018 | 405 | 0.030 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2016 | 31 | 0.030 |
Why?
|
| Chicago | 1 | 2020 | 1430 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2016 | 336 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2016 | 263 | 0.030 |
Why?
|
| Genotype | 1 | 2020 | 1853 | 0.030 |
Why?
|
| Quinazolines | 1 | 2016 | 212 | 0.030 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2011 | 7 | 0.020 |
Why?
|
| Contraindications | 1 | 2011 | 70 | 0.020 |
Why?
|
| Cytodiagnosis | 1 | 2011 | 46 | 0.020 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2011 | 68 | 0.020 |
Why?
|
| Systole | 1 | 2011 | 115 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2011 | 301 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2011 | 1172 | 0.020 |
Why?
|
| Recurrence | 1 | 2011 | 1143 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 1541 | 0.020 |
Why?
|
| Ventricular Function, Left | 1 | 2011 | 607 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2011 | 1605 | 0.020 |
Why?
|
| Biomarkers | 1 | 2011 | 1768 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 3465 | 0.010 |
Why?
|